Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions

American Journal of Gastroenterology

Volumn 97, Issue 8, 2002, Pages 1951-1958

  Straus, Walter L ^a,b   Ofman, Joshua J ^c,d   MacLean, Catherine ^e,f   Morton, Sally ^f   Berger, Marc L ^a   Roth, Elizabeth A ^f   Shekelle, Paul ^g,h  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c AHCPR Southern California Evidence Based Practice Center   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e Zynx Health   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RAND CORPORATION   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CLINICAL TRIAL; DYSPEPSIA; EPIGASTRIC PAIN; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; META ANALYSIS; NAUSEA; NOMENCLATURE; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARDIZATION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DYSPEPSIA; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TERMINOLOGY;

EID: 0036678344     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04262-4     Document Type: Article

References (78)

1. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology
2. Ulcer complications and nonsteroidal anti-inflammatory drugs
3. Gastrointestinal side-effects of NSAIDs in the community
4. Nonsteroidal anti-inflammatory drugs and dyspepsia in the elderly
5. AGA technical review: Evaluation of dyspepsia
6. Dyspepsia. Definition and discussion of nomenclature
7. Endoscopy in the evaluation of dyspepsia
8. Campylobacter pylori. An advance in understanding of dyspepsia and gastritis
9. Definition and investigation of dyspepsia. Consensus of an international ad hoc working party
10. Functional dyspepsia: A classification with guidelines for diagnosis and management
11. Definitions of dyspepsia
12. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy
13. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?
14. Definitions of dyspepsia: Time for a reappraisal
15. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia
16. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
17. Some statistical methods for combining experimental results
18. No effect of piroxicam on achilles tendinopathy. A randomized study of 70 patients
19. A comparative study of piroxicam (Feldene), diclofenac and placebo in osteoarthritis
20. Antrafenine, naproxen and placebo in osteoarthritis: A comparative study
21. Efficacy and tolerance of a novel precision-dose formulation of indomethacin: Double-blind trials in rheumatoid arthritis and osteoarthritis
22. Tiaprofenic acid (Surgam) in arthritic conditions: A randomized double-blind comparison with placebo in a multi-centre trial
23. Comparative study of sulindac (clinoril) and ibuprofen (brufen) in osteoarthrosis
24. Effect of clinoril (sulindac, msd), piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hypertension
25. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia
26. Floctafenine (Idarac) in the management of rheumatoid arthritis
27. A double-blind study comparing ibuprofen 1800 mg or 2400 mg daily and placebo in sports injuries
28. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis
29. Double blind comparison of indometacin and cloximate, a new nonsteroid antirheumatic agent (Doppelblindstudie Zwischen Indometacin und Cloximat, Einem Neuen Nichtsteroidalen Antrirheumatikum)
30. A double blind, placebo controlled study of piroxicam in the management of acute musculoskeletal disorders
31. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers
32. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normal volunteers. A comparative study
33. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers
34. Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo
35. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis
36. Single and multiple dose analgesic and kinetic studies of mefenamicacid in chronic back pain
37. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration
38. Meclofenamate sodium in the treatment of post-traumatic edema. Report of a controlled double-blind study
39. Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada
40. Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience
41. Treatment of ocular inflammation with diclofenac sodium: Double-blind trial following cataract surgery
42. A comparative study of sulindac (MK 231), aspirin and placebo in coxarthritis: Some problems related to the clinical evaluation of analgesic, anti inflammatory drugs
43. Effects of ibuprofen on normal subjects clinical and routine and special laboratory assessments
44. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee
45. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers
46. Short-term efficacy and tolerance of tiaprofenic acid (surgam) in rheumatoid arthritis and osteoarthritis. Multicentre placebo-controlled trials
47. Diflunisal. A placebocontrolled trial
48. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee
49. Treatment of acute low-back pain with Piroxicam: Results of a double-blind placebo-controlled trial
50. Interrelationships between helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers
51. Tolmetin versus placebo for the treatment of rheumatoid arthritis: A sequential double-blind clinical trial
52. Efficacy and safety of Etodolac and Naproxen in patients with osteoarthritis of the knee: A double-blind, placebo-controlled study
53. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal injury and gastroduodenal mucosal prostaglandins
54. A crossover clinical trial of piroxicam, indomethacin and ibuprofen in rheumatoid arthritis
55. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee
56. Piroxicam spares buprenorphine after total joint replacement - Controlled study of pain treatment in 81 patients
57. Oxaprozin in the treatment of patients with tendinitis and bursitis: Comparison with phenylbutazone and placebo
58. A double blind comparison of niflumic acid with phenylbutazone, oxyphenylbutazone and placebo in the treatment of osteoarthrosis
59. Benoxaprofen improves psoriasis. A double-blind study
60. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison
61. A double-blind comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis
62. Tolmetin sodium, a new anti-arthritis drug: Double-blind and long term studies
63. Efficacy and tolerability of lysine-acetylsalicylate on soft tissue rheumatism
64. Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia
65. National guidelines on dyspepsia
66. Guidelines for dyspepsia treatment in Japan
67. Guidelines for dyspepsia management in general practice using focus groups
68. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
69. Management of dyspepsia: Report of a working party
70. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking
71. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis
72. NSAID-induced gastroduodenal damage: Is prevention needed? A review and metaanalysis
73. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
74. Nonsteroidal antiinflammatory drugs, ulcers and risk: A collaborative meta-analysis
75. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy
76. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
77. Dyspepsia in NSAID users: The size of the problem